Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T39554
(Former ID: TTDI01541)
|
|||||
Target Name |
MAPK/ERK signaling pathway (MAPK pathway)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Mild neurocognitive disorder [ICD-11: 6D71] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | REN-1654 | Drug Info | Phase 2 | Cognitive impairment | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | REN-1654 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. | |||||
REF 2 | ClinicalTrials.gov (NCT00107055) Study of REN-1654 in Patients With Sciatica Pain. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.